Mednet Logo
HomePediatric Hematology/OncologyQuestion

What is your treatment approach for a pediatric patient with H3K27M-mutant diffuse midline glioma following progression after radiation therapy?

1 Answers
Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Colorado Anschutz Medical Campus

First, if the patient is at least six months from initial radiation and has had a reasonable initial response, reirradiation is the best proven treatment for recurrence. We would also encourage enrollment on a clinical trial (the DMG National Tumor Board is a helpful resource for determining for whi...

Register or Sign In to see full answer

What is your treatment approach for a pediatric patient with H3K27M-mutant diffuse midline glioma following progression after radiation therapy? | Mednet